Citigroup Upgrades Dr Reddy's Laboratories to Buy, Raises Price Target to $1450

Citigroup analyst Vivek Agrawal has upgraded Dr Reddy's Laboratories (NYSE: RDY) from a 'Sell' to a 'Buy' rating. Additionally, the price target for the stock has been raised significantly from $1,040 to $1,450.